Applying the Potter Box to Merck's Actions Regarding the Painkiller Vioxx

In this article, we explain how to focus on empirically applying ethical decisions, using Potter Box, a model Ralph Porte created as an analytical tool for evaluating corporate decision-making ethics I will. Facts concerning litigation were ethically considered by pharmaceutical company Merck and its analgesic Vioxx. Using the pottery box model, you can explain and research cases against Merck based on ethical considerations. The results not only show how decisions are made but also show the overall consideration of the decision.

Vioxx / Merck outlines an analgesic Vioxx by Medck & Co. It was released in 1999. Since its launch, it has been used by over 20 million Americans. Vioxx has been on the market for about 5 years and does not adequately warn about its risk. In September 2004, Merck removed Vioxx from the market, previous studies showed that patients who used it more than 18 months had twice the risk of heart attack or stroke. - Merck 's case study fact Facts: Merck is one of the world' s largest pharmaceutical companies. Merck is to lose the patent protection of the two best-selling drugs, which accounts for the majority of the annual turnover of $ 2 billion. Merck began investing in millions of dollars of research (up to a billion dollars), and within three years Merck was able to discover four powerful medicines.

In 2004, Merck was heavily criticized for being called Vioxx. In patients with analgesics, Vioxx causes cardiac complications and increases the likelihood of stroke. Some of them are fatal. However, according to the article, the most important issue is not Vioxx itself, but Merck has known that Vioxx has these side effects since 2000, clearly leading to serious PR problems. - Introduction Since its launch as a small pharmacy Merck has always focused on improving customer health and well-being. With the expiration of pharmaceutical patents and the emergence of genotypes of its top products, Merck's strategy is to do something unexpected. Merck is focusing on reducing costs to raise the price of old products and switch to new drugs protected by patents, but to compete with GM similar products.